1 2 3 4 5 6 7 8 9
далее an open 4-center tnal Semm Arthritis Rheum 2004,33 311-319 22 Hampton К, Chamberlain M , Menon D et al Coagulation and fibnnolytic activity in Behcet's disease Thromb Haemost 1991,66 292-294 23 Mader R , Ziv M , Adami M etal Trirombophilic factors and their relation to thromboembolic and other clinical manifestations in Behcet's disease J Rheum , 1999 26 2404-2408 24 Насонов E Л , Штугман В 3 Насонова В А Перспективы применения циклоспорина А в ревматологии Российская ревматология 1999, №2, 18-25 25 NussenblattR Rodngues M Archives of Ophthalmol 1982,100 1146-1149 26 ElidanJ CohenE LeviH etal Effect of cyclosponne A on the hearing loss in Behcet's disease Ann Oto Rhinol Laryngol 1991, 100 464-468 27 Masuda К Nakajima A Urayama A et al Double-marked trial of cyclosponne in Behcet's disease Lancet, 1989, 1 1093-1096 28 Kaklamani V Kaklamani P Treatment of Behcet's disease and update Seminar Arthritis Rheumatology 2001,30 299-312 29 Ben Ezra D Cohen E, Chajek Т et al Evalutional therapy versus cyclosponne A in Behcet's syndrome Transplant Proc 1988 20 136-143 30 Kotake S Higashi К, Joshikawa К et al Central nervous system symptom in patients with Behcet's disease receiving cyclosponne therapy Ophthalmology 1999, 106 586-587 31 Akpolat T, Dipi В Oguz J et al Behcet's disease and renal failure Nephrology Dial transplant, 2003, 18 888-891 32 SaravananV Hamilton J Advances in the treatment of rheumatoid arthritis old versus new therapies Expert Opin Pharmacotherapy 2002, 3 845-856 33 Makamura S , Yamakawa T , Sugita M et al The role of tumor-necrosis factor alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmic Vis Sci 1994, 35 3884-3889 34 Mege J , Dilsen N , Sangueldoice V et al Overproduction on monocyte derived tumor necrosis factor alpha, interleukin (IL) 6 IL-8 and increased neutrophil superoxid generation in Behcet's disease J Rheumatology 1993, 20 1544-1549 35 Sayinalp N , Ozcebe 0 , Ozdemir 0 et al Cytokines in Behcet's disease J Rheumatology, 1996 23 321-322 36 Turan В , Sallati H , Erdi H etal Systemic levels of T cells regulatory cytokines IL IOandlL-12 in Behcet's disease soluble TNF-R -75 as biologic marker of disease activity J Rheumatology 1997, 24 128-132 37 Markomichefakis N , Theodossiadis P Pantelia E et al Infliximab for chronic cystoid macular edema associated with uveitis Am J Ophthalmology 2004 138 648-650 38 Ahmad T Wallace G , James T et al Mapping the HLA association in Behcet's disease a role for tumor necrosis factor polymorphisms7 Arthr Rheum 2003 48 807-813 39 Banares A, Abasalo L Maccaron P et al Treatment of refractory posterior uveitis with anti-TNF-alpha (infliximab) Arthr Rheum 2001,44 190-227 40 SfikakisP Theodossiadis P Katsian С et al Effect of infliximab on Sight-threatening panuveitis in Behcet's disease Lancet, 2001, Jul 28, 358 (9278) 295-296 41 Алекберова 3 С , Танковский В Э , Елонаков А В Применение инфликсимаба при Бояезни Бехчета Русский медицинский журнал 2005, 13 (24) далее ...